Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

PixelOptics sees $45mm with its Series D round

Executive Summary

Eyeglass company PixelOptics Inc. has completed its $45mm Series D venture round. The financing consisted of $35mm in equity from returning backers Safeguard Scientifics (lead with a $25mm investment; it also contributes two board members), Delphi Ventures, the Carlyle Group, Longitude Capital, and Stark Investments. Horizon Technology Finance provided the $10mm in debt. PixelOptics recently launched emPower!, its electronic focusing waterproof and shock-resistant eyeglasses for presbyopia. A full North American launch is planned for the immediate future, with a European introduction within the next year. The Series D comes just two months after the company raised $5.5mm in debt.
Deal Industry
  • Medical Devices
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Venture Financing

Related Companies

UsernamePublicRestriction

Register